NEW YORK (GenomeWeb) – Natera went public late last week, raising $180 million in an initial public offering on the Nasdaq Global Select Market.

The San Carlos, California-based reproductive health molecular diagnostics firm offered 10 million shares of common stock at an offering price of $18 per share. The underwriters on the offering — Morgan Stanley, Cowen and Co., Piper Jaffray, R.W. Baird, and Wedbush Securities — have an over-allotment option to purchase an additional 1.5 million shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.